Affinity Asset Advisors »

Perspective Therapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Perspective Therapeutics (CATX) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Perspective Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Perspective Therapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Perspective Therapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-06-30 $5.5M 550k 9.97

More positions owned by Affinity Asset Advisors

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Xenon Pharmaceuticals (XENE)
Apogee Therapeutics (APGE)
Madrigal Pharmaceuticals (MDGL)
Cerevel Therapeutics Hldng I (CERE)
Arcellx Common Stock (ACLX)
Crinetics Pharmaceuticals In (CRNX)
Nurix Therapeutics (NRIX)
Celldex Therapeutics Com New (CLDX)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Alnylam Pharmaceuticals Note 1.000% 9/1 (Principal)
Beigene Sponsored Adr (BGNE)
Alkermes SHS (ALKS)
Nuvalent Inc-a (NUVL)

View all positions for Affinity Asset Advisors

Top funds holding Perspective Therapeutics

Commodore Capital
Henderson Group
BlackRock
Avidity Partners Management
Vanguard Group
Deerfield Management Company
Nicholson Wealth Management Group
Octagon Capital Advisors
Marshall Wace
Geode Capital Management
Hills Bank And Trust Company
State Street Corporation
Ghost Tree Capital
Paradigm Biocapital Advisors
Sphera Funds Management

View all funds holding Perspective Therapeutics